![Michael J. Parker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historial de carrera de Michael J. Parker
Antiguos cargos conocidos de Michael J. Parker.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Tercica, Inc.
![]() Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Corporate Officer/Principal | - | 03/02/2014 |
Bayer Corp.
![]() Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | Corporate Officer/Principal | 01/01/1999 | 01/06/2001 |
Formación de Michael J. Parker.
University of Glasgow | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 3 |
Reino Unido | 2 |
Operativa
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Tercica, Inc.
![]() Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Bayer Corp.
![]() Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Michael J. Parker
- Experiencia